Literature DB >> 582826

TSH-responsive adenylate cyclase activity in thyroid tissue from patients with Graves' disease.

C M Rotella, P Fani, A L Tanini, P Cicchi, R S Toccafondi, P Arcangeli.   

Abstract

Basal adenylate cyclase activity of thyroid plasma membranes obtained from six patients with Graves' disease was slightly but not significantly lower than normal (83.3 +/- 13.9 pmol cAMP/10 min/mg of protein versus 120.9 +/- 19.5 pmol cAMP/10 min/mg of protein). In five of these patients the adenylate cyclase activity was stimulated by bovine TSH with an apparent Km value similar to that of normal thyroid (3.1 +/- 0.5 X 10-9 M versus 3.4 +/- 0.6 X 10-9 M). The response to prostaglandin E2 was also normal. In the sixth patient adenylate cyclase activity was stimulated by prostaglandin E2 but not by bovine TSH. The distribution of basal adenylate cyclase activity in various gradient layers was studied in two TSH-responsive patients. A relative increase of this activity was found in the denser layer when compared to normal thyroid tissue. This could be the expression of an altered ratio between the protein and lipid components of the plasma membranes in patients with Graves' disease.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 582826     DOI: 10.1007/BF03349276

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  15 in total

1.  Propranolol increases binding of thyrotropin to thyroid membranes.

Authors:  N J Marshall; S von Borcke; A Florin-Christensen; R P Ekins
Journal:  Nature       Date:  1977-07-07       Impact factor: 49.962

2.  Studies on inhibition of TSH stimulation of adenyl cyclase activity in thyroid plasma membrane preparations by propranolol.

Authors:  N J Marshall; S Von Borcke; P G Malan
Journal:  Endocrinology       Date:  1975-06       Impact factor: 4.736

3.  Human thyroid adenyl cyclase-stimulating activity in immunoglobulin G of patients with Graves' disease.

Authors:  J Orgiazzi; D E Williams; I J Chopra; D H Solomon
Journal:  J Clin Endocrinol Metab       Date:  1976-02       Impact factor: 5.958

4.  TSH stimulation of 32P incorporation into phospholipids of thyroids from patients with Graves' disease.

Authors:  P B Schneider
Journal:  J Clin Endocrinol Metab       Date:  1974-01       Impact factor: 5.958

5.  The binding of thyrotropin to isolated bovine thyroid plasma membranes.

Authors:  S M Amir; T F Carraway; L D Kohn; R J Winand
Journal:  J Biol Chem       Date:  1973-06-10       Impact factor: 5.157

6.  Abnormal adenylate cyclase activity and altered membrane gangliosides in thyroid cells from patients with Graves' disease.

Authors:  G Lee; E F Grollman; S M Aloj; L D Kohn; R J Winand
Journal:  Biochem Biophys Res Commun       Date:  1977-07-11       Impact factor: 3.575

7.  New in vitro tests to detect the thyroid stimulator in sera from hyperthyroid patients by measuring colloid droplet formation and cyclic AMP in human thyroid slices.

Authors:  T Onaya; M Kotani; T Yamada; Y Ochi
Journal:  J Clin Endocrinol Metab       Date:  1973-05       Impact factor: 5.958

8.  Effects of long-acting thyroid stimulator (LATS) and LATS protector on human thyroid adenyl cyclase activity.

Authors:  P Kendall-Taylor
Journal:  Br Med J       Date:  1973-07-14

9.  The influence of propranolol on the thyrotropin receptor.

Authors:  T F Davies; S M McLachlan; P M Povey; B R Smith; R Hall
Journal:  Endocrinology       Date:  1977-04       Impact factor: 4.736

10.  The different modes of action of thyrotropin and prostaglandin E1 on cyclic adenosine 3',5'-monophosphate synthesis in human thyroid, as studied by sequential stimulations.

Authors:  N Takasu; S Sato; T Yamada; M Makiuchi; R Furihata
Journal:  Horm Metab Res       Date:  1976-05       Impact factor: 2.936

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.